Sanofi: ASCO - Sarclisa is First Anti-CD38 to Significantly Improve Progression-Free Survival in Combination With VRd for Newly Diagnosed Transplant-Ineligible Multiple Myeloma in Phase 3
June 04, 2024
June 04, 2024
PARIS, France, June 4 (TNSres) -- Sanofi, a life sciences company, issued the following news release:
* * *
* Sarclisa, in combination with standard-of-care bortezomib, lenalidomide and dexamethasone (VRd) followed by Sarclisa-Rd reduced the risk of recurrence or death by 40% versus VRd followed by Rd in the investigational use for transplant-ineligible newly diagnosed multiple myeloma patients
* Key primary endpoint of progression-free survival met, demon . . .
* * *
* Sarclisa, in combination with standard-of-care bortezomib, lenalidomide and dexamethasone (VRd) followed by Sarclisa-Rd reduced the risk of recurrence or death by 40% versus VRd followed by Rd in the investigational use for transplant-ineligible newly diagnosed multiple myeloma patients
* Key primary endpoint of progression-free survival met, demon . . .